AI in healthcare award for NHS deployment of Ibex’s Galen Breast

Ibex Medical Analytics, the University of Nottingham and a consortium of NHS Trusts, have been announced as the winners of the UK Artificial Intelligence in Health and Care Award, recognising the deployment of Ibex's Galen Breast solution across five NHS trusts and delivering improved breast cancer diagnosis and laboratory efficiency.

Galen Breast supports pathologists by providing AI-based tools and insights that help detect and grade different types of breast cancer. The solution will be deployed at Nottingham University Hospitals, Cambridge University Hospitals, North West Anglia NHS Foundation Trust, Betsi Cadwaladr University Health Board and University Hospitals Birmingham. Pathologists from each trust will use Ibex's Galen Breast to analyse a total of 10,000 biopsies as part of routine practice and evaluate how the Ibex technology helps improve the quality of diagnosis, reduce case review time, and impacts overall cost-effectiveness of breast cancer diagnosis and turnaround time for patients. With increasing attention on the potential to improve people's health through digital technologies, both patient and public involvement will be core to the project, led by the Oxford Academic Health Science Network.

The Phase 4 awards enable AI technologies that have market authorisation to generate important evidence targeting large-scale commissioning or deployment. As the most mature category, with only two Phase 4 projects granted in 2023, the award will enable Ibex and its partners to demonstrate clinical and economic utility of Galen Breast in real-world implementations in the NHS.

Professor Emad Rakha, Honorary Consultant Pathologist at the University of Nottingham and Nottingham University Hospitals NHS trust, and the study's principal investigator added: "Over the last several years in the UK, cancer cases increased while the number of pathologists decreased, resulting in record-high workloads for pathology departments. Timely and accurate diagnosis can significantly impact breast cancer survival rates, making Ibex's solution a vital and welcome addition into NHS trusts."

"We are proud to receive this award from the NIHR and NHS, said Chaim Linhart, PhD, Co-Founder and Chief Technology Officer of Ibex Medical Analytics. "This award and other programs supported by the UK government signify its commitment to making the NHS the global leader in implementing AI technologies in healthcare. Our trusted and robust AI platform is already helping UK pathologists improve the quality of prostate cancer diagnosis, and we are eager to work with our NHS partners on expanding our collaboration to support breast cancer diagnosis and treatment."


Latest Issues

Med-Tech Innovation Expo

NEC, Birmingham
5-6 June, 2024


DoubleTree by Hilton Brighton Metropole
10-12 June, 2024

Infection Diagnostics Symposium 2024

IET Austin Court, Birmingham
26-27 June, 2024

SHOT Symposium 2024

Mercure Manchester Piccadilly Hotel
9 July, 2024